2.68
price down icon2.55%   -0.07
pre-market  Vorhandelsmarkt:  2.69   0.010   +0.37%
loading
Schlusskurs vom Vortag:
$2.75
Offen:
$2.75
24-Stunden-Volumen:
6.06M
Relative Volume:
0.69
Marktkapitalisierung:
$2.37B
Einnahmen:
$1.31M
Nettoeinkommen (Verlust:
$-597.65M
KGV:
-2.7629
EPS:
-0.97
Netto-Cashflow:
$-425.62M
1W Leistung:
-7.59%
1M Leistung:
-6.62%
6M Leistung:
-16.77%
1J Leistung:
-53.71%
1-Tages-Spanne:
Value
$2.64
$2.80
1-Wochen-Bereich:
Value
$2.64
$2.95
52-Wochen-Spanne:
Value
$1.83
$7.48

Immunitybio Inc Stock (IBRX) Company Profile

Name
Firmenname
Immunitybio Inc
Name
Telefon
(844) 696-5235
Name
Adresse
3530 JOHN HOPKINS COURT, SAN DIEGO
Name
Mitarbeiter
671
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
IBRX's Discussions on Twitter

Vergleichen Sie IBRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IBRX
Immunitybio Inc
2.68 2.56B 1.31M -597.65M -425.62M -0.97
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-20 Hochstufung Piper Sandler Neutral → Overweight
2025-03-06 Eingeleitet H.C. Wainwright Buy
2025-01-10 Eingeleitet BTIG Research Buy
2023-05-12 Herabstufung Piper Sandler Overweight → Neutral
2022-08-03 Eingeleitet Jefferies Buy

Immunitybio Inc Aktie (IBRX) Neueste Nachrichten

pulisher
02:36 AM

LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper - Benzinga

02:36 AM
pulisher
Jul 21, 2025

What drives ImmunityBio Inc. stock priceRapid market gains - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

ImmunityBio: A High-Conviction Play on ANKTIVA's Expanding Indication and Immune-Boosting Platform - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval - Seeking Alpha

Jul 21, 2025
pulisher
Jul 20, 2025

ImmunityBio Inc. Stock Analysis and ForecastSkyrocketing returns - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about ImmunityBio Inc. stockExceptional financial outcomes - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

Is ImmunityBio Inc. a good long term investmentExplosive market performance - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 15, 2025

ImmunityBio’s Anktiva Rollercoaster: From FDA Rejection and 55% Stock Drop to Approval - TradingView

Jul 15, 2025
pulisher
Jul 14, 2025

ImmunityBio Settled With Investors Over FDA Rejection Drama— How to Claim Your Share - TradingView

Jul 14, 2025
pulisher
Jul 12, 2025

ImmunityBio: High Stakes On ANKTIVA's Growth Amidst FDA Friction And Financial Pressures - Seeking Alpha

Jul 12, 2025
pulisher
Jul 11, 2025

ImmunityBio’s Innovative Approach to Ovarian Cancer: A Phase 2 Study Update - TipRanks

Jul 11, 2025
pulisher
Jul 09, 2025

ImmunityBio Stock Surges Amid Promising Trial Updates - TipRanks

Jul 09, 2025
pulisher
Jul 09, 2025

ImmunityBio’s Innovative Approach to Bladder Cancer Treatment: A Clinical Study Update - TipRanks

Jul 09, 2025
pulisher
Jul 08, 2025

Bullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA Authorization - MSN

Jul 08, 2025
pulisher
Jul 08, 2025

ImmunityBio Granted UK Approval for Bladder Cancer Treatment - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

ImmunityBio: D. Boral Capital Maintains Buy, Raises PT to $30 from $30 - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN

Jul 08, 2025
pulisher
Jul 07, 2025

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Lelezard

Jul 07, 2025
pulisher
Jul 07, 2025

ImmunityBio's ANKTIVA® Secures UK Approval: A Catalyst for Global Oncology Leadership - AInvest

Jul 07, 2025
pulisher
Jul 07, 2025

Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire

Jul 07, 2025
pulisher
Jul 07, 2025

ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView

Jul 07, 2025
pulisher
Jul 06, 2025

13 Stocks Under $5 With High Upside Potential - Insider Monkey

Jul 06, 2025
pulisher
Jul 04, 2025

UK Regulator OKs ImmunityBio's Bladder Cancer Treatment for New Indication - MarketScreener

Jul 04, 2025
pulisher
Jul 02, 2025

ImmunityBio (IBRX) Rated Buy After FDA Approvals and Pancreatic Cancer Trial Success - Yahoo Finance

Jul 02, 2025
pulisher
Jun 24, 2025

ImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA - Yahoo Finance

Jun 24, 2025
pulisher
Jun 23, 2025

Anktiva Approved For Additional Treatment - Los Angeles Business Journal

Jun 23, 2025
pulisher
Jun 20, 2025

ImmunityBio Approves 2025 Equity Incentive Plan - TipRanks

Jun 20, 2025
pulisher
Jun 17, 2025

ImmunityBio's $10.5M Investor Deal Gets Final OK - Law360

Jun 17, 2025
pulisher
Jun 17, 2025

ImmunityBio Gets Final OK for $10.5 Million Investor Settlement - Bloomberg Law News

Jun 17, 2025
pulisher
Jun 12, 2025

ImmunityBio’s ANKTIVA & FDA Expanded Access: Transforming bladder cancer treatment - pharmaphorum

Jun 12, 2025
pulisher
Jun 12, 2025

As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry - newswire.ca

Jun 12, 2025
pulisher
Jun 12, 2025

ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze (NASDAQ:IBRX) - Seeking Alpha

Jun 12, 2025
pulisher
Jun 12, 2025

ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion - MSN

Jun 12, 2025
pulisher
Jun 08, 2025

15 Stocks That Stole The Show Last Week - Insider Monkey

Jun 08, 2025
pulisher
Jun 06, 2025

Deadline to Claim Your Payout from the $10.5M ImmunityBio Settlement Is in 1 Month - TradingView

Jun 06, 2025
pulisher
Jun 05, 2025

Why ImmunityBio, Inc. (IBRX) Skyrocketed Today - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

H.C. Wainwright maintains buy rating on ImmunityBio stock after FDA milestones - Investing.com Nigeria

Jun 04, 2025
pulisher
Jun 04, 2025

ImmunityBio (IBRX) Receives Reiterated Buy Rating from HC Wainwr - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

ImmunityBio (IBRX) Receives Reiterated Buy Rating from HC Wainwright | IBRX Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Cancer Treatment Granted Lymphopenia Indication - Vax-Before-Travel

Jun 04, 2025
pulisher
Jun 03, 2025

ImmunityBio receives FDA Expanded Access authorization for Cancer BioShield - Yahoo Finance

Jun 03, 2025
pulisher
Jun 03, 2025

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer - Bakersfield.com

Jun 03, 2025
pulisher
Jun 03, 2025

ImmunityBio (IBRX) Receives Maintained Buy Rating from D. Boral Capital | IBRX Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

FDA grants expanded access to ImmunityBio’s Anktiva for lymphopenia - Yahoo

Jun 03, 2025
pulisher
Jun 03, 2025

FDA authorizes ANKTIVA for lymphopenia in cancer patients By Investing.com - Investing.com South Africa

Jun 03, 2025

Finanzdaten der Immunitybio Inc-Aktie (IBRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
Kapitalisierung:     |  Volumen (24h):